Apex Laboratory · Compound explained · Evidence checked September 8, 2026
If you arrived asking whether 5-Amino-1MQ “burns fat,” start with what was actually tested. A mouse fat pad, a person’s blood marker and a controlled human weight-loss trial answer different questions. This guide follows that distinction through the chemistry, the experiments and the claims.
- Identity: a charged small molecule, with the salt form specified separately.
- Observed: direct cell and animal experiments, including measurable fat and muscle outcomes.
- Unresolved: human effectiveness, formulation equivalence, side effects and long-term outcomes.
What is 5-Amino-1MQ—and why isn’t it a peptide?
The name abbreviates 5-amino-1-methylquinolinium. The “amino” part describes a chemical group on a ring system; it does not mean the molecule is a sequence of amino acids. Its experimental role is to inhibit nicotinamide N-methyltransferase, shortened to NNMT. The original medicinal-chemistry work compared related ring-based compounds to find features associated with stronger enzyme inhibition. Neelakantan 2017.
159.21 g/mol
The positively charged molecular species listed in PubChem CID 950107.
The iodide reference includes its counterion and has a molecular weight of 286.11 g/mol. A published mouse microbiome study instead specifies a monochloride salt.
These are different reporting bases, not rounding variants. A compound name or a cation mass alone does not identify a vial’s counterion or establish whether its stated amount refers to cation or salt mass. Dimet-Wiley 2022.
That distinction matters when reading analytical records. A molecular ion, a formula for the isolated salt and a labeled amount can describe different parts of the same material. They need to be matched deliberately rather than treated as interchangeable specifications.
How does NNMT connect nicotinamide, NAD+ and methyl groups?
NNMT transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, one form of vitamin B3. The products are 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Nicotinamide can also enter the NAD+ salvage pathway, which cells use to rebuild NAD+. NNMT therefore sits at a junction between metabolism and methyl-group availability; it does not directly convert NAD+ into fat. Pissios 2017. Swaminathan 2017.
One enzyme reaction, two connected metabolic questions
Does the NAD+ story hold up?
The founding compound paper measured metabolites in cultured 3T3-L1 mouse fat cells. Its NAD+ values were about 1.2–1.6 times control levels across several tested concentrations, but the overall analysis did not reach the conventional significance threshold (P = 0.0568). One concentration had a significant follow-up comparison. The measurements used biological duplicates. SAM also changed, while nicotinamide and SAH did not show significant overall changes. Neelakantan 2018.
That is a useful mechanistic clue with a small experimental base. It is not evidence that 5-Amino-1MQ reliably raises NAD+ throughout the human body, reverses aging or reproduces the effects of exercise.
Why did researchers become interested in NNMT?
Early work found active NNMT in cultured fat cells and human and mouse adipose-tissue samples. A later study reduced NNMT expression in mice using an antisense approach and measured changes in energy expenditure and resistance to diet-induced obesity. Those studies helped establish the target, but they did not test a human 5-Amino-1MQ treatment. Riederer 2009. Kraus 2014.
NNMT is responsive to its surroundings. Glucose deprivation changed its expression in cultured adipocytes through an mTOR-related mechanism. Reviews of metabolic syndrome and broader NNMT biology describe roles that vary across tissues and disease models. A higher or lower enzyme level therefore cannot be interpreted as universally good or bad. Ehebauer 2020. Metabolic-syndrome review, 2024. NNMT pathways review, 2024.
What have studies actually found about fat loss?
The clearest early evidence comes from a direct compound experiment in diet-induced obese male mice, not from a human before-and-after series. In the 2018 paper, nine mice per group remained on a high-fat diet during an 11-day comparison. Neelakantan 2018.
Average body-weight change from each group’s baseline
Both groups remained on the high-fat diet.
Approximately 2.0 g less body weight.
Approximately 0.6 g more body weight.
The result answers “did this compound change adiposity in this mouse experiment?” It does not answer how quickly a person would lose weight, whether a specific body region would change, or whether the effect would persist after stopping.
A diet change was part of the experiment
In a separate study, obese mice switched to a leaner, lower-calorie diet. The compound-plus-diet group lost more weight and fat than the group receiving the same diet change alone. The reported fat-mass decrease was approximately 29.3% versus 2.9% from baseline across roughly seven weeks. This comparison is not “compound alone versus no intervention.” Sampson 2021.
The following microbiome paper examined cecal microbial patterns in that diet-and-treatment setting and referred to the earlier study’s experimental design. Changes in bacterial abundance do not, by themselves, show that a microbiome change caused the fat loss or predict a human gut-health benefit. Dimet-Wiley 2022.
Less weight gain, with additional metabolic measurements
Babula and colleagues used three groups of eight obese male mice. Body-composition and insulin measurements through day 28, with terminal analyses after the treatment period, showed limits on weight and fat gains, improved glucose-tolerance measurements and changes in fatty-liver pathology. That is a different outcome from the short study’s absolute weight loss. Babula 2024.
Not every measurement improved: weekly fed-state blood glucose was unchanged. Liver findings in this obesity model are not proof of a treatment for every form of liver injury, or evidence of reduced clinical liver failure in people.
What about muscle preservation or exercise-like benefits?
A 2019 experiment tested the compound after an induced muscle injury in 24-month-old mice. Regenerating muscle fibers were larger, and peak torque normalized to body weight was about 67% higher in the treated group. When torque was normalized to muscle-fiber area, the difference was not significant. The experiment concerned recovery in an aged, injured muscle—not muscle gain in healthy adults. Neelakantan 2019.
A 2024 study used an eight-week design with aged mice assigned to sedentary or weighted-wheel exercise conditions, each with or without the compound. Grip-strength measurements favored the treated groups, including the combined intervention. Many molecular changes associated with exercise were still distinct from those associated with the inhibitor. This does not establish that a person can replace exercise, preserve all lean mass during weight loss, or improve athletic performance with 5-Amino-1MQ. Aged-mouse exercise study, 2024.
Which findings belong to this compound—and which belong to the target?
The distinction is easiest to see by separating what researchers changed. A shared enzyme name does not make different interventions interchangeable.
On a narrow screen, scroll the comparison horizontally. The region is keyboard focusable.
| What changed? | What the experiment can address | What it cannot establish |
|---|---|---|
| 5-Amino-1MQ exposure Cells, rats or mice in specified experiments |
Effects of the tested material under those conditions, including its exposure and off-target activity. | A human benefit, a retail product’s equivalence, or an established human safety profile. |
| NNMT gene expression or deletion | How reducing or removing the target influences a particular biological system. | That a small molecule will reproduce the same duration, tissue distribution or degree of inhibition. |
| Another NNMT inhibitor | Results for that chemotype and formulation. | That its absorption, selectivity or effects also belong to 5-Amino-1MQ. |
| Human NNMT associations | Relationships between expression, genetic variation and measured health outcomes. | The outcome of giving 5-Amino-1MQ to those participants. |
Why target evidence needs its own column
A genetic NNMT study reported improved insulin sensitivity in some mouse conditions without improved glucose tolerance, with effects varying by sex and diet. Another compound, JBSNF-000028, improved glucose tolerance even in NNMT-knockout mice. That observation suggests that its glucose effect was not explained solely by NNMT inhibition. Neither paper is a human 5-Amino-1MQ efficacy trial. Brachs 2019. Ruf 2022.
Are there any human studies?
Human research on NNMT exists. A 2015 paper examined NNMT expression and its product in cohorts undergoing abdominal surgery, exercise or bariatric surgery. It associated these measurements with metabolic status; the participants were not given 5-Amino-1MQ. Kannt 2015.
A 2025 paper analyzed genetic and medical-record data from 612 people with excessive alcohol consumption. A score based on variants associated with lower NNMT protein was linked to a lower incidence of alcohol-associated fatty liver. This was a retrospective target-validation study using genetic variation, not a trial administering an NNMT inhibitor. Its findings do not identify a safe exposure or prove that taking 5-Amino-1MQ would reproduce the association. Human genetic-target study, 2025.
What the current search did—and did not—find. On September 8, 2026, exact compound-name searches in ClinicalTrials.gov returned no matching intervention records. A broader NNMT search returned two studies whose interventions were unrelated to 5-Amino-1MQ. PubMed searches using the compound names, related nomenclature and current NNMT literature did not identify a results-reporting controlled human 5-Amino-1MQ trial.
That dated finding leaves human effectiveness and safety unresolved. It does not claim that all unpublished work or every registry worldwide has been examined.
Human before-and-after photographs, anecdotes and vendor descriptions cannot resolve that gap. They generally cannot separate the material’s effect from diet, exercise, other exposures, selection of favorable results or uncertainty about the material itself.
Oral absorption and half-life: why the species matters
There are direct pharmacokinetic studies, but they are animal studies. A 2021 rat paper measured oral bioavailability of 38.4%. The 2024 mouse paper reported 3.5%. Those figures came from different species and study conditions; neither is a validated absorption figure for a human capsule. Rat pharmacokinetic study, 2021. Babula 2024.
Terminal half-life describes the later decline in measured plasma concentration. It is not the duration of a benefit. Scroll this table on narrow screens.
| Actual animal measurement | Reported result | Interpretation limit |
|---|---|---|
| Rat, 2021 Intravenous / oral |
Terminal half-life approximately 3.8 / 6.9 hours; oral bioavailability 38.4%. | Not a human half-life or a result for a retail oral product. |
| Mouse, 2024 Intravenous / oral |
Terminal half-life approximately 6.3 / 14.8 hours; oral bioavailability 3.5%. | The longer oral terminal half-life did not mean greater systemic exposure. |
| Mouse, 2024 Subcutaneous exposure |
Approximately 13.3 hours after a single exposure and 12.8 hours after repeated exposure. | Different route and conditions; not interchangeable with the rat results or a human schedule. |
| Human | No validated value identified in the reviewed sources. | Animal values cannot supply an evidence-based human timing recommendation. |
The mouse study also reported a half-life under seven minutes in isolated mouse hepatocytes. That is a laboratory metabolic-stability measurement, not a plasma half-life. Combining all of these values into one supposedly universal number would erase the distinctions that make the data useful.
What is known about side effects and other uncertainties?
No reliable human side-effect frequency can be calculated from these studies. “No observable adverse effects” in a short mouse experiment describes that observation period and its measurements. It is not a long-term toxicology assessment or evidence that a person reporting fatigue or another symptom has a known, predictable 5-Amino-1MQ reaction.
The 2024 mouse research program included a laboratory screen against other targets. At one tested concentration, 5-Amino-1MQ inhibited monoamine oxidase-A (MAO-A) by 67.4%. The authors identified this as an off-target activity needing further optimization. A single-concentration assay is not an established clinical interaction, but it is a concrete reason to reject “perfectly selective” or “no interaction risk” claims. Babula 2024.
NNMT is not a universal metabolic off-switch
In a 2025 liver ischemia-reperfusion study, reducing hepatic NNMT made injury worse in the experimental setting, while increasing NNMT or adding its product 1-MNA was protective. A 2026 study linked reduced NNMT to impaired decidualization in endometrial cells and examined uterine gene silencing in pregnant mice. Liver injury study, 2025. Endometrial NNMT study, 2026.
These findings concern different target manipulations and disease models. They do not show that 5-Amino-1MQ causes those outcomes in humans. They do show why results from obese fat tissue cannot be generalized to every tissue, disease or reproductive setting.
Several key metabolic and muscle publications share investigators. The 2024 obesity paper discloses relationships with Ridgeline Therapeutics. Those disclosures do not invalidate the data; they matter when judging how much independent replication and clinical confirmation a claim has received.
Is it FDA approved, and what does the compounding notice mean?
No approved medicine was identified in the current FDA approval-database search under the compound names used here. In a January 20, 2026 warning letter, FDA stated that the inspected facility’s drug products made with 5-Amino-1MQ did not qualify for section 503B exemptions because the substance was not on the relevant bulks list and was not used to compound a drug on the shortage list.
That is a specific US regulatory finding. It is not a worldwide legal classification, a manufacturing endorsement or evidence that a research material has an approved human use.
What can a research-material record establish?
A product label and an analytical report answer a material question, not an effectiveness question. Start with the exact identity and salt form, the labeled configuration, the report’s sample or lot identifier, and the measurement basis. A chromatographic peak-area result does not establish human safety or demonstrate that a commercial material is equivalent to one used in a paper.
The 5-Amino-1MQ product listing provides the commercial configurations and its report handoff. Use the applicable record in Lab Verified for the stated methods and results, and the COA reading guide to interpret those fields. This article does not make a new shipment-lot, counterion, purity-threshold or stability claim.
How does it compare with NAD+ or MOTS-c?
They are different materials with different research questions. 5-Amino-1MQ is an enzyme inhibitor; NAD+ is a coenzyme; MOTS-c is a peptide investigated in metabolic signaling. The MOTS-c research guide examines its own evidence. Shared interest in metabolism does not validate a combined protocol, prove additive effects or establish safety for a combination.
Frequently Asked Questions About 5-Amino-1MQ
Is 5-Amino-1MQ a peptide?
No. 5-Amino-1MQ is a synthetic small molecule built on a methylquinolinium ring system. Its amino group does not make it a chain of amino-acid residues. Peptide-shop placement does not change that chemistry.
What does 5-Amino-1MQ do?
It inhibits the enzyme nicotinamide N-methyltransferase, or NNMT. Cell and mouse experiments have examined changes in fat accumulation, metabolic measurements and muscle function. Those experimental findings do not establish a human treatment benefit.
Does 5-Amino-1MQ shrink fat cells or cause weight loss?
Smaller fat cells and lower fat-pad mass were measured in a short study of diet-induced obese mice. Other mouse studies also found metabolic effects. Controlled human weight-loss results were not identified in the literature and registry searches reviewed here, so the mouse findings cannot predict a personal result.
Are there human studies of 5-Amino-1MQ?
There is human research on NNMT expression and genetic variation. Those studies did not administer 5-Amino-1MQ. The September 8, 2026 search found no matching intervention record in ClinicalTrials.gov and no results-reporting controlled human 5-Amino-1MQ trial in the examined PubMed records. This is a dated search finding, not proof that every unpublished study is known.
Does 5-Amino-1MQ increase NAD+?
A small experiment in cultured mouse fat cells reported higher NAD+ measurements, with a significant comparison at one tested concentration but a nonsignificant overall analysis. That result supports further investigation; it does not establish a sustained NAD+ increase in people or an anti-aging effect.
Do capsules or oral 5-Amino-1MQ work like other forms?
Human formulation equivalence has not been established. Rat and mouse studies reported very different oral bioavailability, and their formulations and experimental conditions differed. A compound being absorbed in an animal does not validate a retail capsule or establish a human benefit.
What is the half-life of 5-Amino-1MQ?
Published terminal half-lives vary by species and route. The rat study reported approximately 3.8 hours after intravenous exposure and 6.9 hours after oral exposure; a separate mouse study reported different values. No validated human half-life was identified. These animal measurements are not a timing or administration recommendation.
What side effects or interaction risks are known?
The reviewed evidence does not establish a human side-effect frequency or a safe exposure. A laboratory screen in the 2024 mouse research program found MAO-A inhibition at one tested concentration. That is an off-target signal requiring investigation, not a measured clinical interaction rate. Short animal observations do not establish long-term human safety.
Is 5-Amino-1MQ FDA approved?
No FDA-approved medicine was identified under the compound names searched in the FDA approval database. A January 20, 2026 FDA warning letter specifically stated that the inspected facility’s 5-Amino-1MQ drug products did not qualify for section 503B compounding exemptions. That finding is not an approval, a worldwide legal classification or a statement that a research product is suitable for human use.
Is there evidence for combining 5-Amino-1MQ with NAD+ or MOTS-c?
An overlapping metabolism topic does not establish that a combination is effective or safe. The studies reviewed here do not validate a human 5-Amino-1MQ and NAD+ or MOTS-c combination, sequence or schedule. The individual compounds also have different identities and experimental evidence.
References and source context
Primary experiments and reviews are distinguished in the discussion above. The existing research references are retained, with additional direct pharmacokinetic, muscle and human-target studies. A citation’s presence does not mean it tested this compound in humans.
- Riederer M et al. Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine. 2009. Atherosclerosis. PMID 18996527.
- Kraus D et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. 2014. Nature. PMID 24717514.
- Kannt A et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. 2015. Diabetologia. PMID 25596852.
- Pissios P et al. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. 2017. Trends in endocrinology and metabolism: TEM. PMID 28291578.
- Neelakantan H et al. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. 2017. Journal of medicinal chemistry. PMID 28548833.
- Swaminathan S et al. Crystal structures of monkey and mouse nicotinamide N-methyltransferase (NNMT) bound with end product, 1-methyl nicotinamide. 2017. Biochemical and biophysical research communications. PMID 28720493.
- Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. 2018. Biochemical pharmacology. PMID 29155147.
- Brachs S et al. Genetic Nicotinamide N-Methyltransferase (Nnmt) Deficiency in Male Mice Improves Insulin Sensitivity in Diet-Induced Obesity but Does Not Affect Glucose Tolerance. 2019. Diabetes. PMID 30552109.
- Neelakantan H et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. 2019. Biochemical pharmacology. PMID 30753815.
- Ehebauer F et al. Glucose availability regulates nicotinamide N-methyltransferase expression in adipocytes. 2020. Life sciences. PMID 32112869.
- Dimet-Wiley A et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. 2022. Scientific reports. PMID 35013352.
- Ruf S et al. Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. 2022. Scientific reports. PMID 36104373.
- Sun WD et al. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome. 2024. Frontiers in pharmacology. PMID 38919254.
- Babula JJ et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. 2024. Diabetes, obesity & metabolism. PMID 39161060.
- Park J et al. Exploring NNMT: from metabolic pathways to therapeutic targets. 2024. Archives of pharmacal research. PMID 39604638.
- Sampson CM et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. 2021. Scientific reports. PMID 33707534.
- Awosemo O et al. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. 2021. Journal of pharmaceutical and biomedical analysis. PMID 34304009.
- Dimet-Wiley AL et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. 2024. Scientific reports. PMID 38969654.
- Wu B et al. Genetic inhibition of nicotinamide N-methyltransferase and prevention of alcohol-associated fatty liver in humans. 2025. Journal of human genetics. PMID 39695269.
- Yin B et al. NNMT/1-MNA protects against hepatic ischemia-reperfusion injury through the AKT/FOXO1/ANGPT2/JNK axis. 2025. Nature communications. PMID 40404636.
- Yang B et al. Nicotinamide N-methyltransferase deficiency disrupts endometrial decidualization partly through dysregulated H3K27 trimethylation in recurrent implantation failure. 2026. Molecular and cellular endocrinology. PMID 42705148.
Research-use context
This guide explains published research and its limits. It does not provide a dose, administration method, treatment plan or combination schedule. Research materials are not presented as approved medicines or as suitable for human consumption.
